Company / Operating Cash Flow per Share
Theravance Biopharma, Inc. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
$4.82
FY2025
5-year range
-$3.36 / $4.82
FY2021-FY2025
Trend
+2110.3%
vs FY2024
Sector context
#24 of 212
Health Care
What the data says
Operating Cash Flow per Share changed +2110% YoY in FY2025, a notable deviation from the 9-year average annual change of +239%.
Based on SEC 10-K filings.
4.82 in FY2025. Top quartile in the Health Care sector.
Improved from $-0.41 to $4.82 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 212This company $4.82 Sector average -$14.72
▼
+132.7% above sector average
Key checks
Key Insights
- Theravance Biopharma, Inc.'s operating cash flow per share has grown for 3 consecutive years.
- In FY2025, operating cash flow per share increased 2110.3% year-over-year.
- Ranks #24 out of 212 companies in the Health Care sector.
- Lowest operating cash flow per share in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.82 | +2110.3% |
| FY2024 | -$0.24 | +42.0% |
| FY2023 | -$0.41 | +87.7% |
| FY2022 | -$3.36 | -4.1% |
| FY2021 | -$3.23 | +26.4% |
| FY2020 | -$4.39 | -21.6% |
| FY2019 | -$3.61 | -98.4% |
| FY2018 | -$1.82 | +52.2% |
| FY2017 | -$3.81 | -46.0% |
| FY2016 | -$2.61 | +30.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026